Latest Regulatory Filings News

Avecho Biotechnology has inked a decade-long exclusive licensing agreement with Sandoz for its pharmaceutical-grade cannabidiol capsule targeting insomnia in Australia, backed by a US$3 million upfront payment and promising milestone and royalty streams.

Ronin Resources has made significant strides in its La Punilla gold-silver project in Argentina, while navigating socio-political hurdles in Colombia and refining its lithium exploration efforts in Canada. The company maintains a solid cash position as it pursues new business opportunities.

FirstWave Cloud Technology reported a mixed Q3 FY25 with declining cash reserves and ARR but secured a strategic AWS-funded partnership to accelerate cloud service adoption.

Atomos Limited reported a $2.3 million operating cash outflow in Q3 FY25 amid seasonal softness and tariff challenges, while announcing a leadership change and a bold expansion into new product categories beyond its core monitor-recorder business.

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.

Impact Minerals Limited reported a solid cash position of A$3.75 million at quarter-end, supported by a recent equity raise that extends its funding runway to nearly four quarters despite ongoing exploration expenditures.

Quickstep Holdings reported a $5.8 million net operating cash outflow in Q3 FY25 but bolstered liquidity by securing $6.6 million in customer advances and implementing cost controls.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Anteris Technologies Global Corp. has filed an amended 10-K to disclose comprehensive governance, executive pay, and related party transactions for fiscal 2024, completing its annual SEC reporting obligations.